Curative cancer therapy remains a major challenge particularly in cancers displaying
multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a …

Epigenetic dysregulation has long been recognized as a key factor contributing to
tumorigenesis and tumour maintenance that can influence all of the recognized hallmarks of …

Biomarker discovery and validation are necessary for improving the prediction of clinical
outcomes and patient monitoring. Despite considerable interest in biomarker discovery and …

Mitochondria are not only the main energy supplier but are also the cell metabolic center
regulating multiple key metaborates that play pivotal roles in epigenetics regulation. These …

Abstract The Endocrine Society's first Scientific Statement in 2009 provided a wake-up call to
the scientific community about how environmental endocrine-disrupting chemicals (EDCs) …

Epigenetic drug discovery field has evidenced significant advancement in the recent times.
A plethora of small molecule inhibitors have progressed to clinical stage investigations and …

The acquisition of cancer hallmarks requires molecular alterations at multiple levels
including genome, epigenome, transcriptome, proteome, and metabolome. In the past …

The hallmarks of cancer comprise six biological capabilities acquired during the multistep
development of human tumors. The hallmarks constitute an organizing principle for …

Metalloenzymes are central to a wide range of essential biological activities, including
nucleic acid modification, protein degradation, and many others. The role of metalloenzymes …

Cancer stem cells (CSCs) also known as cancer-initiating cells (CIC), are responsible for the
sustained and uncontrolled growth of malignant tumors and are proposed to play significant …